Pink Sheet reports on Aranesp and Procrit concerns

Share this article:
Members of the FDA's Oncologic Drugs Advisory Committee expressed concerns at a May meeting that DTC advertising of Amgen's Aranesp and Johnson & Johnson's Procrit have given patients a lopsided impression of the drugs' risk/benefit profile, The Pink Sheet reported. The state of New York subpoenaed Aranesp promotional materials that month.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions